|
Intravenous Levodopa for the Diagnosis of Parkinson's Disease Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Intravenous Levodopa for the Diagnosis of Parkinson's Disease conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Intravenous Levodopa for the Diagnosis of Parkinson's Disease Clinical research trials and Intravenous Levodopa for the Diagnosis of Parkinson's Disease health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Intravenous Levodopa for the Diagnosis of Parkinson's Disease. Intravenous Levodopa for the Diagnosis of Parkinson's Disease Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Intravenous Levodopa for the Diagnosis of Parkinson's Disease clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Intravenous Levodopa for the Diagnosis of Parkinson's Disease condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Intravenous Levodopa for the Diagnosis of Parkinson's Disease  Intravenous Levodopa for the Diagnosis of Parkinson's Disease
Intravenous Levodopa for the Diagnosis of Parkinson's Disease
For Condition: Parkinson Disease
Status: Completed
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: Patients with Parkinson's disease have low levels of the neurotransmitter dopamine. Dopamine is responsible for motor function and normal physical activity. Patients with Parkinson's disease typically suffer from tremors, rigid muscles, stooped postures, and walk with a shuffle. The drug levodopa acts as a replacement for dopamine and has been has been used effectively for over 30 years as treatment for Parkinsons disease. Because of its effectiveness, levodopa has been used to distinguish Parkinson's disease from other conditions that may resemble Parkinson's disease. Traditionally, levodopa has been given as a pill. In this study, researchers would like to inject levodopa directly into a vein (intravenous) in order to diagnose cases of Parkinson's disease. This method provides immediate results and allows doctors to adjust the dose of levodopa very carefully. Because the intravenous method of giving levodopa is less practical than oral medication, it is not an available alternative for the routine treatment of Parkinson's disease. However, it may be useful for faster diagnosis of the disease and for determining effective doses of oral medication.
Details: A positive response to levodopa is now considered a condition sine qua non for the diagnosis of idiopathic Parkinson's disease. Under this protocol, patients with parkinsonism of uncertain etiology will be tested for their motor response to intravenous levodopa to aid in the diagnosis of Parkinson's disease. This protocol regulates and stipulates the acute administration of intravenous levodopa and associated safety issues.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: All patients will have parkinsonism of undetermined etiology. Males and females between the ages of 18 and 85 are eligible for the study. No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risks, specifically those who have the following: a history of convulsive, hepatic, or renal disorders; currently receiving treatment for myocardial infarction, arrhythmia or cardiac failure; and pregnant women or anyone not practicing an effective means of birth control.
Total Enrollment: 25
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990072; 99-N-0072
Study Start Date: March 29, 1999
Record last reviewed: March 11, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001928
Other Parkinson Disease Studies:
1. Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease
2. Treatment of Parkinson's Disease with a Transdermal Skin Patch
3. GM1 Ganglioside Effects on Parkinson’s Disease
4. Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients
5. Spheramine® in advanced Parkinson’s disease (The STEPS Trial)
Related Studies:
Other Parkinson Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Intravenous Levodopa for the Diagnosis of Parkinson's Disease
|
|
|
|
|
|
|
|
